Web Analytics
top of page

1993: Barbour & Fish reveal that OspA vaccine trials are underway and start trashing Lyme victims.


Here we learn that the Phase I and Phase II trials of the OspA vaccines are underway, while Alan Barbour (owner of the ImuLyme OspA patent) and Durland Fish (founding member of the ALDF.com) proceed to trash victims of Chronic Lyme/Sepsis, saying it is a disease of hysteria or catastrophizing...because they know by now that OspA is making people sick, especially after 2 injections.  

"However, if a skin lesion is absent, a situation that may occur in 10% or more of infections [4,5], nothing in the clinical presentation can clearly distinguish early Lyme disease from other acute, febrile summer illnesses of temperate latitudes. Later manifestations of Lyme disease, such as arthritis or carditis, can be attributed to other disorders. Neurologic symptoms, especially those involving changes in cognitive functions, are especially difficult to interpret [69- 71]. Moreover, factors such as the premorbid personality and a tendency to somatization may determine the length of convalescence and the response to postinfection fatigue and joint aches [71,72]. Even if the original diagnosis of Lyme disease is undisputed, lingering or recurrent symptoms, many of which are also characteristic of chronic fatigue syndrome or fibromyalgia, may not be attributable to persistent infection."

"Decisions on diagnostic criteria, treatment strategies, research-funding allocation, and insurance reimbursement are being made. Policy-makers are under pressure from some health professionals and lay persons who believe that the spectrum of B. burgdorferi disease is broader than the limits accepted by most peer-reviewed medical journals. The conditions in this larger set include degenerative, inflammatory, and neuropsychiatric conditions not previously thought to be ameliorated by antibiotics [81]. Alternative views of diagnostic criteria and treatment strategies have been presented primarily at regional meetings sponsored by patient advocacy groups and in newsletters devoted to Lyme disease. More recently, the influence of these points of view on the last international scientific meeting on Lyme disease was such that several additional abstracts, which had originally been rejected, were permitted presentation [82]."


Alan Barbour & Durland Fish 
bottom of page